Advertisement
UK markets open in 4 hours 16 minutes

  • NIKKEI 225

    37,789.76
    +161.28 (+0.43%)
     

  • HANG SENG

    17,546.35
    +261.81 (+1.51%)
     

  • CRUDE OIL

    83.85
    +0.28 (+0.34%)
     

  • GOLD FUTURES

    2,347.10
    +4.60 (+0.20%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • Bitcoin GBP

    51,539.30
    +170.26 (+0.33%)
     

  • CMC Crypto 200

    1,392.59
    +10.02 (+0.72%)
     

  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

AstraZeneca's Tagrisso to cost $12,750 for a month's supply

Reuters - UK Focus

LONDON, Nov 17 (Reuters) - AstraZeneca (NYSE: AZN - news) 's new lung cancer pill Tagrisso, which won early U.S (Other OTC: UBGXF - news) . approval on Friday, will cost $12,750 for a month's supply.

A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral cancer therapies, including AstraZeneca's Iressa.

AstraZeneca has previously said it believes Tagrisso could generate peak sales of $3 billion a year, making it a key product in the group's growing oncology portfolio. (Reporting by Ben Hirschler; Editing by Mark Potter)